Ablvax is a therapeutic vaccine currently being evaluated as a treatment for patients with resistant chronic myeloid leukemia (CML).
Under terms of the agreement, MolecularMD will perform molecular diagnostic tests on all patients participating in the company’s ongoing trial to assess whether the disease is in remission.
The multicenter trial plans to enroll a total of 60 patients of which all will be evaluated by MolecularMD.
“We understand that the approach being studied by Abvlax offers the greatest opportunity for long-term remission for patients with CML. The ability to reliably and consistently measure molecular evidence of CML will be a key factor to interpreting the benefit of Ablvax,” noted Dr Brian Druker, scientific founder of MolecularMD.
“We are confident that their experience will be of great help in analyzing response patterns for our patients,” commented Rosemary Mazanet, CEO, Breakthrough Therapeutics.